The DOI matches its Crossref record.
Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma
Open accessAbstract
RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVES: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma. METHODS: In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression. MEASUREMENTS AND MAIN RESULTS: RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84). CONCLUSIONS: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lambrecht, B. N., Hammad, H., & Fahy, J. V. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.018 · Cited by 1,039
International consensus statement on allergy and rhinology: Allergic rhinitis – 2023
Wise, S. K., Damask, C., Roland, L. T., Ebert, C., Levy, J. M., Lin, S., Luong, A., Rodriguez, K., Sedaghat, A. R., Toskala, E., et al. (2023) · International Forum of Allergy & Rhinology · doi:10.1002/alr.23090 · Cited by 507
Role of viral infections in the development and exacerbation of asthma in children
Jartti, T., & Gern, J. E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.08.003 · Cited by 474
Self-citationResearch Progress in Atopic March
Yang, L., Fu, J., & Zhou, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01907 · Cited by 268
Biologics and airway remodeling in severe asthma
Varricchi, G., Ferri, S., Pepys, J., Poto, R., Spadaro, G., Nappi, E., Paoletti, G., Virchow, J. C., Heffler, E., & Canonica, W. G. (2022) · Allergy · doi:10.1111/all.15473 · Cited by 254
Metadata
- Authors
- Esquivel, A., Busse, W. W., Calatroni, A., Togias, A. G., Grindle, K. G., Bochkov, Y. A., Gruchalla, R. S., Kattan, M., Kercsmar, C. M., Khurana Hershey, G., Kim, H., Lebeau, P., Liu, A. H., Szefler, S. J., Teach, S. J., West, J. B., Wildfire, J., Pongracic, J. A., & Gern, J. E.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-10-15
- Volume
- 196
- Issue
- 8
- Pages
- 985-992
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W2626956924
- Cited by
- 251
- References
- 0
- FWCI
- 19.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. https://app.cochat.ai/papers/10.1164/rccm.201701-0120oc
- The paper
- Esquivel, A., Busse, W. W., Calatroni, A., Togias, A. G., Grindle, K. G., Bochkov, Y. A., Gruchalla, R. S., Kattan, M., Kercsmar, C. M., Khurana Hershey, G., Kim, H., Lebeau, P., Liu, A. H., Szefler, S. J., Teach, S. J., West, J. B., Wildfire, J., Pongracic, J. A., & Gern, J. E. (2017). Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201701-0120oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.